Insight into Dexamethasone’s Benefits in Severe COVID-19
Insight into Dexamethasone’s Benefits in Severe COVID-19
The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.
Insight into Dexamethasone’s Benefits in Severe COVID-19
Insight into Dexamethasone’s Benefits in Severe COVID-19

The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.

The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.

clinical data
Special Report
Surgisphere Sows Confusion About Another Unproven COVID-19 Drug
Surgisphere Sows Confusion About Another Unproven COVID-19 Drug
Catherine Offord | Jun 16, 2020
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
Surgisphere Fallout Hits African Nonprofit’s COVID-19 Efforts
Surgisphere Fallout Hits African Nonprofit’s COVID-19 Efforts
Catherine Offord | Jun 7, 2020
The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.
<em>Lancet, NEJM </em>Retract Surgisphere Studies on COVID-19 Patients
Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients
Catherine Offord | Jun 4, 2020
All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.
Concerns Build Over Surgisphere&rsquo;s COVID-19 Dataset
Concerns Build Over Surgisphere’s COVID-19 Dataset
Catherine Offord | Jun 2, 2020
NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.
Exclusive
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Catherine Offord | May 30, 2020
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.
A New Way to Establish Cause and Effect in Epidemiology?
A New Way to Establish Cause and Effect in Epidemiology?
Rachael Moeller Gorman | Jan 1, 2020
A technique called Mendelian randomization is overturning the conclusions of observational studies in public health. But researchers question whether the method can overcome its fundamental limitations.
Biogen Presents Data on Efficacy of Alzheimer&rsquo;s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
The Open Data Explosion
The Open Data Explosion
Viviane Callier | Dec 31, 2018
Scientists are working to maximize the benefits and minimize the costs of sharing.
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Abby Olena | Dec 3, 2018
YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.